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ABSTRACT

The most abundant immune cell types of the tumor microenvironment macrophages recruited
tumor-eluted factors. The role of these immune cells in tumor progression, and the interplay
between tumor and immune cells is an emerging field of research with potential for novel
treatment strategies. Here, a TIE2 expressing macrophage (TEM) subtype is integrated into a
virtual tumor model. Within the 2D microenvironment, the TEM will differentiate from an
extravasated monocyte precursor, congregate around the abluminal side of the vasculature in
response to a chemoattractant gradient, secrete cytokines which favor differentiation of a
separate angiogenic macrophage subtype [1]. The effects of macrophage populations on tumor
progression on angiogenic activity and tumor growth will be examined.
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NOMENCLATURE
M1
M2
TEM
TAM

= tumoricidal macrophage subtype
= tumorigenic macrophage suntype
= TIE2-expresseing (angiogenic) macrophage subtype
= Tumor-Associated Macrophage

𝑀𝜙

= Monocyte (macrophage precursor)

TAF = Tumor Angiogenisis Factor
Ang2 = Angiopoietin2
IL-10 = Interleukin 10
NO = Nitric oxide
VEGF = Vascular Endothelial Growth Factor
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I. INTRODUCTION

A. Background on Tumor-Associated Macrophages

The role of tumor-associated macrophages (TAMs) in tumor growth (Guo,
Buranych et al. 2013, Chanmee, Ontong et al. 2014, Guo, Buranych et al. 2014, Tripathi,
Tewari et al. 2014) and treatment response (Squadrito and De Palma 2011, De Palma and
Lewis 2013) has been the subject of increased study in the past several years. What has
emerged is that populations of tumor-associated macrophages are diverse in both
phenotype and lineage (Laoui, Movahedi et al. 2011, Italiani and Boraschi 2014). While
an increased presence of macrophages at a tumor lesion site is generally correlated with
poor prognosis, within the phenotypic range of TAMs are subtypes that produce various
and even opposing roles in tumor progression (Chanmee, Ontong et al. 2014) (Roca,
Varsos et al. 2009). The range of tumorigenic and tumoricidal phenotypes reflects the
conflicting cues within the tumor environment. While the immune response to tumor
growth may begin as primarily tumoricidal, with macrophages of the M1 or classically
activated type targeting tumor cells, cytokines secreted by the tumor exploit the
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relatively fluid phenotype of the TAMs to promote tumor growth and survival (Yuan,
Hsiao et al. 2015) via the M2 subtype.
A third, more recently discovered subtype, the TIE-2 receptor expressing
macrophage (TEM), develops from a distinct monocyte precursor, and displays unique
and non-redundant behaviors highly relevant to tumoral angiogenesis (De Palma,
Murdoch et al. 2007, Lewis, De Palma et al. 2007, Venneri, Palma et al. 2007, De Palma,
Venneri et al. 2008). In particular, the critical role of TEMs in tumor angiogenesis and
vascular remodeling (De Palma, Murdoch et al. 2007, Lewis, De Palma et al. 2007,
Venneri, Palma et al. 2007, De Palma, Venneri et al. 2008, Riabov, Gudima et al. 2014,
Stockmann, Schadendorf et al. 2014) was shown by increased TEM infiltration following
administration of anti-angiogenic agents (Welford, Biziato et al. 2011) as well as the
blocking of the angiogenic factor Angiopoietin-2 (ANG2), a TIE2 ligand associated with
activated endothelial cells. This lead to regression of tumor vasculature and arrested
tumor progression (Mazzieri, Pucci et al. 2011).

B. Background on Macrophage Subtypes
The M1 extreme of the macrophage activation spectrum is commonly associated
with inflammatory responses and tumoricidal activity by release of proinflammatory
cytokines and oxygen species such as nitric oxide (NO), which encourage tumor cell
apoptosis (Plank and Sleeman 2003) (Edin, Wikberg et al. 2012). Its presence in the
tumor microenvironment is correlated with reduced angiogenesis required to supply the
increased tumor metabolic needs, and thus reduced tumor growth and survival (Yuan,
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Hsiao et al. 2015) (Italiani and Boraschi 2014). The relative proportion of the M1
macrophages generally decreases with tumor progression. The M1 subtype is identified
by surface receptors CD14++CD16− (Plank and Sleeman 2003).
The M2 or alternatively activated macrophages encompass a broader family of
macrophages involved in tissue healing under normal conditions. Within the tumor
microenvironment, they are recruited for tumor progression (Chanmee, Ontong et al.
2014), and generally comprise a larger portion of the TAMs in advanced tumors (Sica
and Mantovani , Chanmee, Ontong et al. 2014). Hypoxia-induced factors such as VEGFA, endothelin-2, and interleukin-10 secreted in the tumor environment encourage
differentiation towards the M2 phenotype (Murdoch, Giannoudis et al. 2004). Within the
tumor microenvironment, M2s secrete factors such as TGF-β1 which facilitates cancer
cell proliferation (Leonard, Curtis et al. 2016) (Italiani and Boraschi 2014), VEGF-A
which promotes angiogenesis and recruits additional macrophages, and MMP-9 which
facilitates angiogenesis by degrading the extracellular matrix (Chanmee, Ontong et al.
2014). The proportion of M2 macrophages in the microenvironment tends to increase
with tumor progression. The M2 subtype is identified by surface receptors
CD14dimCD16+ (Italiani and Boraschi 2014).
TIE2 expressing macrophages (TEMs) are a tumorigenic subtype upregulated in a
variety of environments where angiogenesis occurs, including tumor lesions (Matsubara,
Kanto et al. 2013) and for post-ischemic recovery (Patel, Smith et al. 2013). They have
been found in breast cancer metastatic lymph nodes (Kim, Kang et al.), and in colorectal
metastases to the liver (Catarinella, Monestiroli et al.). They can be identified by the
expression of the TIE2 receptor on their surface which, curiously, is also expressed by
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blood vessel endothelial cells, where they are integral to angiogenic pathways and
development (Plank and Sleeman 2003, Matsubara, Kanto et al. 2013). Recent research
indicates that TEMs are recruited to the tumor microenvironment at an early phase of
development. There, they are believed to play a pivotal role in tumor neovascular
development by activating the “angiogenic switch” – a transition that occurs when a
tumor begins to recruit nearby vasculature to supply its increased metabolic demands (De
Palma and Naldini 2011).

C. Specific Roles of TEMs
The chief contribution of TEMs to tumor progression appears to be facilitation of
angiogenesis through structural and paracrine support. The macrophage’s eponymous
receptor, TIE2, binds the growth factors angiopoietin 1 and 2. In addition to having a
direct chemotactic effect on the TEMs (Coffelt, Tal et al. 2010) interactions with
angiopoietins lead to the upregulation of several factors necessary to angiogenic
processes, including MMP-9, CTSB, and IL-10, not dissimilar to role of the M2 subtype
(Coffelt, Tal et al. 2010, Coffelt, Chen et al. 2011). However, TEMs have a more
multifaceted involvement in angiogenesis (De Palma, Venneri et al. 2008). In addition to
upregulating these factors in TEMs, angiopoietin 2 (Ang2) acts as a chemoattractant,
causing the TEMs to congregate along the abluminal side of vessels (Lewis, De Palma et
al. 2007). Here, TEMs are thought to directly facilitate vessel sprouting by providing both
a structural scaffold and paracrine support for endothelial sprouts, aiding in their growth
(De Palma, Murdoch et al. 2007), and preventing collapse due to the high hydrostatic
pressure associated with the tumor microenvironment (Matsubara, Kanto et al. 2013). As
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a tumor grows and its metabolic needs increase, TEMs continue to fill a supportive role
in the growth and maturation of the neovasculature that supplies it with nutrients and
oxygen (Matsubara, Kanto et al. 2013) . In a 2008 study by De Palma et al. comparing a
tumor model with an intact and TEM-knockout population of tumor associated
macrophages, the tumors with an intact population showed just under a four-fold increase
in vascular development in comparison to the TEM-ablated population (De Palma,
Venneri et al. 2008).
In addition to their more direct roles in facilitating neovascular development,
TEMs also contribute to the cocktail of other tumor-friendly cytokines in the
microenvironment. IL-10 is an immune cytokine secreted from most leukocytes,
including macrophages, as well as tumor cells themselves (Hamidullah, Changkija et al.
2012). It has pleiotropic effects in the tumor microenvironment, being implicated in both
suppression of tumorigenic cytokines such as IL-6 [31], and in improved immune escape,
poor prognosis, and advanced cancer stage (Kozlowski, Zakrzewska et al. 2003,
Dehqanzada, Storrer et al. 2007, Esquivel-Velazquez, Ostoa-Saloma et al. 2015, Capone,
Guerriero et al. 2016). While it is known to be upregulated in several cancer types,
including breast cancer (Beckebaum, Zhang et al. 2004, Esquivel-Velazquez, OstoaSaloma et al. 2015) a consensus has yet to be reached on whether it is a definitive
indicator of tumor progression and patient prognosis, as some studies have suggested that
its overexpression leads to subsequent immune rejection of the tumor (Mocellin,
Marincola et al. 2005). IL-10 is also known to play a role in inducing infiltrating
monocytes to adopt the tumorigenic M2 phenotype (Italiani and Boraschi 2014). TIE2-
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expressing macrophages are known to secrete IL-10, and thus may contribute to the
increased ratio of M2 to M1 macrophages in the tumor microenvironment.

D. Contribution to Previous Models
Previous mathematical modeling work has explored critical aspects of tumor-associated
macrophage activity. Owen and Sherratt (Owen and Sherratt 1998, Owen and Sherratt
1999) presented a model in which macrophages entered the tumor environment to
selectively target tumor cells. Later models were developed to simulate macrophages
primed to destroy cancer cells on contact (Byrne, Cox et al. 2004) or by drug delivery
(Owen, Byrne et al. 2004). In (Webb, Owen et al. 2007) it was shown that effective
macrophage targeting of hypoxic tumor cells would benefit from non-cell-cycle dependent
drugs or limited-diffusivity.

In (Owen, Stamper et al. 2011) it was found that the

combination of conventional and macrophage-based therapies using magnetic
nanoparticles could be synergistic. In (Chen, Bobko et al. 2014) the role of tumor
macrophage hypoxia inducible factors (HIFs) in chemotherapy effectiveness was
evaluated. Recently, a model exploring the efficacy of nanoparticle albumin-boundpaclitaxel (nAb-PTX) using macrophages in a multistage vector system as a therapy for
hypervascularized breast cancer metastases in the liver was developed (Leonard, Curtis et
al. 2016).
The interplay of the various monocyte subtypes with the changing tumor
microenvironment presents a relevant and challenging task which may benefit from a
systems analysis perspective. To this end, recent mathematical modeling and
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computational simulation work (Leonard, Curtis et al.) has evaluated the role of
macrophages in the tumor microenvironment to gain insight into implications for cancer
treatment and drug delivery. In this study, a computational framework to further evaluate
the role of TEMs in relation to M1 and M2 macrophage phenotypes on the growth of
vascularized tumor lesions is developed.
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III. PROCEDURE

The computational model builds upon recent work simulating generic tumorassociated macrophages (TAMs) in a vascularized tumor environment (Leonard, Curtis et
al. 2016), in which a breast cancer lesion metastasized to the liver was simulated – in an
microenvironment that is known to favor the recruitment of TAMs (Bocuk, Krause et al.
2015). In (Leonard, Curtis et al. 2016), macrophages were utilized as a drug vector, and
their performance was evaluated experimentally and via computational simulation. Here,
we do not assume that drug is vectored by macrophages, and instead focus on the effects
of various macrophage population subtypes on the tumor lesion progression.
Briefly, the model is composed of a tumor lesion in a 2D grid of preexisting
vasculature as previously described (Macklin, McDougall et al. 2009, van de Ven, Wu et
al. 2012, Wu, Frieboes et al. 2013, Leonard, Curtis et al. 2016). Two types of
macrophage subtypes are defined – the M1 and M2. The TEM subtype is added as a third
population that promotes angiogenesis for tumors in the liver (Matsubara, Kanto et al.).
Given that the monocytes are not biologically active in the model, a simplifying
assumption is made that TIE2 expressing macrophage differentiate from the same
monocyte precursor as the M1 and M2 macrophage subtypes. As the TEM phenotype
appears in the environment, its effects are modeled as follows:
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•

Increasing differentiation of TIE2 macrophages from a monocyte precursor
with tumor progression

•

Semi-stochastic movement of TEMs along a chemoattractant gradient (Ang2)
secreted by the peritumoral vasculature, as well as monocyte attractant from
the hypoxic regions of the tumor.

•

The protein released by the TEMs is modeled after IL-10 to examine the
effects of cytokine release in the context of immunomodulatory activity.

•

Increased M2 differentiation in response to TEM-eluted IL-10 in the system

•

Increased angiogenesis and resilience of tumoral neovasculature

The relevant model parameters are outlined in Table I.

TABLE I
MACROPHAGE-ASSOCIATED PARAMETERS.
Parameter
Description
Physiological Parameters
% of macrophages per tumor total cells

Value

Reference

10%

TEM-driven tumor neovasculature increase
TEM portion of differentiated macrophages
M2/M1 ratio in highly metastatic tumors
M2/M1 ratio in moderately metastatic tumors

~4-fold
55-70%
2.06
0.77

Calibrated to match (Leonard, Curtis
et al. 2016)
(De Palma, Venneri et al. 2008)
(Venneri, Palma et al. 2007)
(Cui 2013)
(Cui)

A. Tumor Growth
The tumor growth model is based on Macklin et al. (Macklin, McDougall et al.
2009) and builds upon (Wu, Frieboes et al. 2013, Leonard, Curtis et al. 2016).
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Simulation of tumor growth begins with a small lesion in a 2D grid of blood vessels
representing a regularly-spaced capillary grid. The tumor progression is modeled in
discrete time increments; the tumor conditions are evaluated, updated, and recorded every
0.075 days. Advection of the tumor and advancement of its boundary are subject to
changes in the microenvironment such as fluid pressure, diffusion of hypoxic proteins
and other angiogenic factors, and concentration of oxygen, glucose and other vital
nutrients (here, simplified as oxygen only). Altogether, the tumor microenvironment may
be described in four regions based on oxygen and proliferation levels. These are:
•

Necrotic region, ΩN, in which oxygen levels are insufficient for viability.

•

Hypoxic region, ΩH, in which oxygen levels are sufficient for viability but not
proliferation.

•

Proliferating region, ΩP, in which oxygen levels are sufficient for proliferation.

•

Normal (non-tumoral) tissue.
Tumor boundary advancement with velocity 𝑉𝑐 through the porous extracellular

matrix of the surrounding normal tissue is based on Darcy’s law (Macklin, McDougall et
al. 2009):

𝑉𝑐 = −𝜇∇𝑃 + 𝜒𝐸 ∇E

(1)

where μ is tissue mobility, encompassing the roles of cell-cell and cell-matrix adhesion, P
is oncotic pressure, 𝜒𝐸 is haptotaxis, and ∇E is the density of the extracellular matrix. Cell
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density in the proliferating region is constrained to a value at or below 70% of the tumor
volume, with extracellular matrix comprising the remaining volume.
Via a simplifying assumption of uniform density E in the proliferating tumor
region, the relationship between velocity change and tumor growth is (Macklin,
McDougall et al. 2009):

∇ ∙ 𝑉𝑐 = 𝜆𝑝

(2)

where 𝜆𝑝 is the non-dimensionalized net tumor proliferation rate (described below).
As oxygen falls below the threshold for a proliferation state in regions distant
from vasculature, hypoxic tissue regions develop and release tumor angiogenic factor
(TAF) and other factors (see Table II).

TABLE II
CHEMOKINE CHARACTERISTICS
Chemokine

Function

M1f

M1 differentiation

M2f

M2 differentiation

IL-10

TEM-eluted factor

T2f

TEM differentiation

Ang2

TEM chemoattractant

Source

Proliferating & hypoxic
tumor cells
Proliferating & hypoxic
tumor cells
TEM
Proliferating & hypoxic
tumor cells
Neovasculature

MW (Da) Fraction of
TAF
Diffusivity
21000

1

18606

3.7606

18606

3.7606

60179

1

~70000

0.26591
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TAF diffuses outward through the tumor and into the surroundings, where it
triggers endothelial cell sprouts in the peritumoral vascular grid. Additionally, TAF
triggers extravasation of macrophages, analogous to the action of VEGF on macrophage
recruitment to the tumor (Lewis and Murdoch , Hsu, Poché et al.). If oxygen falls below
a vital threshold, necrotic tissue develops within the tumor and degrades. The tumor
model main parameters are shown in Table III.

TABLE III
MAIN PARAMETERS AND ASSOCIATED VALUES
Parameter

Value

Reference
-1

Tumor native mitosis rate
Tumor tissue threshold for hypoxia

0.5 day
0.5750

Tumor tissue threshold for necrosis

0.5325

Oxygen diffusivity
Oxygen transfer rate from vasculature
Oxygen uptake rate by proliferating tumor cells
Oxygen uptake rate by hypoxic tumor cells
Oxygen uptake rate by tumor microenvironment
Oxygen decay rate

1 (*)
5 (*)
1.5 (*)
1.3 (*)
0.12 (*)
0.35 (*)

Estimated
Calibrated to match
(Leonard, Curtis et al.
2016)
Calibrated to match
(Leonard, Curtis et al.
2016)
(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)

Note: (*) value is rescaled by the square of the simulation system characteristic length (1
cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen
diffusivity (Nugent and Jain) (1 x 10-5 cm2 s-1).
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B. Angiogenesis and Vascular Development
The angiogenesis model, simulating the model by (McDougall, Anderson et al. 2006) and
based on (Macklin, McDougall et al. 2009, Wu, Frieboes et al. 2013), outlines the
mechanical and chemical effects of tumor proliferation on the growth, maturation, flow,
flux, and collapse of the surrounding vasculature. The vasculature is simplified to a grid,
from which irregular vessels sprout and grow in response to gradients of factors and
pressures produced by the tumor tissue.
Each vessel sprout grows semi-stochastically, with the probability of growing in
four directions weighted by the presence of TAF gradient produced by ΩH. The
sensitivity of the vascular growth is increased in response to contact with factors secreted
by the TEMs. The magnitude of this response is tuned to correlate with the four-fold
increase in vasculature surface area found to result from TEM-eluted factors by De Palma
et al (De Palma, Venneri et al. 2008).
The change ∆R in radii R of the vessels are modeled according to pressures
imposed by the fluid carried within them (Pries, Secomb et al. 1998, McDougall, Anderson et
al. 2002, McDougall, Anderson et al. 2006, Macklin, McDougall et al. 2009),

∆𝑅 = (𝑆𝑤𝑠𝑠 + 𝑆𝑝 + 𝑆𝑚 − 𝑆𝑠 )𝑅

(3)

where 𝑆𝑤𝑠𝑠 is the local wall shear stress stimulus, 𝑆𝑝 is the intravascular pressure
stimulus, 𝑆𝑚 is the flow carrying hematocrit stimulus, and 𝑆𝑠 is the natural shrinking
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tendency of the vessel as a result of the properties of the basal lamina. This natural
shrinking tendency is a constant value 𝑆𝑠 (Pries, Hopfner et al. 2010) unless the pressure
PC within the vessel reaches a critical pressure 𝑃𝐶𝑇 , at which point the shrinking tendency
increases proportionally to the pressure with a rate 𝑘𝑝𝑐 to simulate complete vessel
collapse. Vessels may partially recover if the stress is relieved (Wu, Frieboes et al. 2013):

𝑆𝑠 = 𝑘𝑠

𝑖𝑓 𝑃𝐶 ≤ 𝑃𝐶𝑇

(4)

𝑆𝑠 = 𝑘𝑠 +𝑘𝑝𝑐 (𝑃𝑐 − 𝑃𝐶𝑇 )

𝑖𝑓 𝑃𝐶 > 𝑃𝐶𝑇

(5)

In the model, the effect of TEM proximity at a given location is incorporated to
provide a protective effect on the neovasculature. Specifically, if a TEM is at an adjacent
location on the matrix to the blood vessel, 1TEM is 1, and 1TEM is 0 if there is no TEM
present. The factor 𝑘𝑎𝑏𝑙𝑢𝑚𝑖𝑛𝑎𝑙 has the effect of greatly reducing the natural shrinking
tendency of the vessel (see Table IV). The change in radius therefore is (Macklin,
McDougall et al. 2009):
∆𝑅 = (𝑆𝑤𝑠𝑠 + 𝑆𝑝 + 𝑆𝑚 − 𝑆𝑠 (1 − 𝑘𝑎𝑏𝑙𝑢𝑚𝑖𝑛𝑎𝑙 𝟏𝑇𝐸𝑀 ))𝑅∆𝑡

(6)

TABLE IV
ANGIOGENESIS COEFFICIENTS
𝑘𝑎𝑏𝑙𝑢𝑚𝑖𝑛𝑎𝑙
𝑘𝑠

Effect of abluminal TEM

10E-5

Calibrated to match (Lewis, De
Palma et al. 2007)

Natural shrinking tendency of the vessel

2.24

(Wu, Frieboes et al. 2013)
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C. Macrophages
Following (Leonard, Curtis et al. 2016), macrophages are simulated to extravasate
in proportion to the local concentration of macrophage chemoattractants (e.g., proangiogenic factors), and to preferentially migrate towards tissue regions (e.g., hypoxic
tissue or vascular sprouts) along the increasing gradient of these chemoattractants.

1. Effects on Tumor Growth
The effects of macrophage variants M1 and M2 are characterized by the action of
their associated tumoricidal and tumorigenic nitric oxide (NO) and tumor growth factors,
respectively. This is simulated by the M2 subtype favoring tumor growth by lowering
the oxygen threshold for tissue to become necrotic while the M1 subtype counters this
effect by secreting NO, which results in tumor tissue death.
The tumor growth factor secreted by the M2 macrophages achieves a transient
local lowering of the viable oxygen threshold – the oxygen level below which tumor cells
die – as follows:

𝑄𝑂𝐿 𝑓 = 𝜆𝑂𝐿 ∙ (1 − 𝑀2𝐺𝐹 ) ∙ (𝑄̅𝑂𝐿 − 𝑄𝑂𝐿 𝑖 ) − 𝜆𝐺𝐹 ∙ 𝑀2𝐺𝐹 ∙ (𝑄𝑂𝐿 𝑖 − 𝑄𝑂𝐿 𝑚𝑖𝑛 )

(7)

where 𝑄𝑂𝐿 𝑓 is the final quiescence oxygen level, 𝜆𝑂𝐿 is the recovery rate of 𝑄𝑂𝐿 𝑓 to the
standard quiescence oxygen level 𝑄̅𝑂𝐿 , 𝑄𝑂𝐿 𝑖 is the initial quiescence oxygen level, 𝑀2𝐺𝐹
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is the local presence of M2 growth factor, 𝜆𝐺𝐹 is the M2 growth factor effect rate, and
𝑄𝑂𝐿 𝑚𝑖𝑛 is the lower bound of the quiescence oxygen level (see Table V)
In addition to inhibiting tumor death, the presence of the M2 growth factor has a
positive effect on the proliferating region as follows:
𝜆𝑀2𝐺𝐹 𝑓 = 𝑀2𝐺𝐹 ∙ 𝑃𝑀2𝐺𝐹 ∙ (0.5 − 𝜆𝑀2𝐺𝐹 𝑖 ) − 𝜆𝑟𝑒𝑐

(8)

where 𝜆𝑀2𝐺𝐹 𝑓 is the final proliferation rate due to the M2 growth factor, 𝑃𝑀2𝐺𝐹 is the M2
growth factor proliferation effect, 𝜆𝑀2𝐺𝐹 𝑖 is the initial proliferation rate due to the M2
growth factor, and 𝜆𝑟𝑒𝑐 is the recovery rate of 𝜆𝑀2𝐺𝐹 to zero (see Table V).
The NO produced by the M1 subtype is incorporated directly into the proliferation
term as follows:
𝑛𝑜𝑛 𝑡𝑢𝑚𝑜𝑟𝑎𝑙:
Ω𝑃 :
𝜆𝑝 = {
Ω𝐻 :
Ω𝑁 :

0
(𝜆𝑀 + 𝜆𝑀2𝐺𝐹 ) ∙ 𝐶𝑂2 − 𝑀1𝑁𝑂 ∙ 𝟏𝑀1 − 𝜆𝐴
𝜆𝑀2𝐺𝐹 ∙ 𝐶𝑂2 − 𝑀1𝑁𝑂 ∙ 𝟏𝑀1 − 𝜆𝐴
− 𝐺𝑁

(9)

where 𝜆𝑀 is the tumor native mitosis rate, 𝐶𝑂2 is the local oxygen concentration, 𝜆𝐴 is the
apoptosis rate due to natural tumoral cell death, 𝑀1𝑁𝑂 is the effect of nitric oxide, and
1𝑀1 is the presence of an M1 macrophage at that location. 𝐺𝑁 is the non-dimensionalized
rate of cell degradation in the necrotic region (see Table V).
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TABLE V
MACROPHAGE EFFECTS ON TUMOR GROWTH
𝑄̅𝑂𝐿
𝑄𝑂𝐿 𝑚𝑖𝑛
𝜆𝑂𝐿
𝜆𝐺𝐹
𝑃𝑀2𝐺𝐹
𝜆𝑟𝑒𝑐
𝑀1𝑁𝑂
𝐺𝑁

Quiescence oxygen level upper bound
Quiescence oxygen level lower bound
Recovery rate of quiescent oxygen level
M2 growth factor effect rate
M2 growth factor proliferation effect coefficient
Recovery rate of 𝜆𝑀2𝐺𝐹 to zero
Effect of nitric oxide coefficient
Rate of cell degradation for the necrotic region.

0.5750
0.5325
0.05(*)
200(*)
1000
0.1(*)
1.5
0.3(*)

(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)
(Wu, Frieboes et al. 2013)
Calibrated to match (Yuan, Hsiao et
al. 2015)
(Wu, Frieboes et al. 2013)

Note: (*) Value is rescaled by the square of the simulation system characteristic length (1
cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen
diffusivity (Nugent and Jain) (1 x 10-5 cm2 s-1).

2. Differentiation
Given the increased ratio of M2/M1 macrophages typical of tumor lesions, the
role of TEM-produced IL-10 on the ratio of M2/M1 macrophage subtypes is modeled. A
target range of 0.32-5.23 was used, to match in vitro data for metastatic tumors in the
liver (Cui 2013).
As monocyte precursors 𝑀𝜙 extravasate from the vasculature in the tumor region,
they come into contact with proteins diffusing from the tumor interior and vasculature
that influence their differentiation. The concentration of factors encouraging
differentiation of given subtypes, analogous to interleukins and angiopoietins, influences
the differentiation rate for each subtype modeled. The rate is dependent on the size of the
interval that a randomly generated number may fall into, as follows:
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𝑀𝜙 = {

𝑀1:
𝑀2:

𝑘𝑀1 ∙ 𝐶𝑀1𝑓
𝑘𝑀2 ∙ (𝐶𝑀2𝑓 + 𝑘 𝑇2𝑀2 ∙ 𝐶𝐼𝐿−10 )

𝑇𝐸𝑀:

(10)

(𝑘 𝑇2 ∙ 𝐶𝑇2𝑓 + 𝑘𝐴𝑛𝑔2 𝐶𝐴𝑛𝑔2 )

where 𝑘𝑀1 , 𝑘𝑀2 , 𝑘 𝑇2 are intensity coefficients tuned to reflect the relative prevalence of
M1 or M2 differentiating monocytes and TIE2 expressing monocytes infiltrating the
tumor, 𝐶𝑀1𝑓 , 𝐶𝑀2𝑓 , 𝐶𝐼𝐿−10 , 𝐶𝑇2𝑓 and 𝐶𝐴𝑛𝑔2 are local concentrations of chemokines and
other factors favorable to M1, M2, or TEM differentiation, and 𝑘𝐴𝑛𝑔2 and 𝑘𝑇2𝑀2 are
intensity coefficients to tune the effect of Ang2 and Il-10 favoring M2 differentiation,
respectively. The values of macrophage-associated variables and coefficients are defined
in Table VI.
TABLE VI
MACROPHAGE DIFFERENTIATION SCALING COEFFICIENTS
𝑘𝑀1
𝑘𝑀2
𝑘 𝑇2

Differentiation of M1 macrophage
Differentiation of M2 macrophage
Differentiation of TEM

20
11
1.5

𝑘𝐴𝑛𝑔2

Effect of Ang2 on TEM differentiation

0.95

𝑘 𝑇2𝑀2

Effect of IL-10 on M2 differentiation

0.055

(Leonard, Curtis et al. 2016)
(Leonard, Curtis et al. 2016)
(Venneri, Palma et al. 2007)
Calibrated to match (Venneri,
Palma et al. 2007, Chanmee,
Ontong et al. 2014)
Calibrated to match (Venneri,
Palma et al. 2007) (Cui 2013)

The concentration of IL-10 in pg/mL is calculated by treating each pixel in the
spatial model as a 3-dimensional voxel. Thus, the final concentration for IL-10 in
simulations with the TEM subtype present are within observed values of 5.6-37 pg/mL
for breast cancers of various TNM stages (Kozlowski, Zakrzewska et al. 2003). The
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exception is a model without the M2 subtype, which achieved reduced tumor and
vascular growth (see Table VII).
TABLE VII
IL-10 CALCULATIONS

Variation
M1 M2 TEM
M2 TEM
M1 TEM
TEM

IL-10
Units
8201.43
7867.44
6978.27
8276.8

Daltons
152598185
146383870
129839715
154000560

pg
0.000253395
0.000243076
0.000215604
0.000255724

Voxel
Area
(mm3)
0.04
0.04
0.04
0.04

IL-10
Concentration
(pg/mm3)
0.00633488
0.00607691
0.00539010
0.00639310

IL-10
Concentration
(pg/mL)
6.3349
6.0769
5.3901
6.3931

3. Chemokine Production and Diffusion
Assuming steady-state conditions, the overall mass balance for a particular
chemokine C is [62]:

0     DC C    production 1  C  1   circulation 1vessel   decay C (11)
C

C

C

C

where DC is diffusivity and  production ,  circulation , and  decay are the (constant) rates of
C

C

chemokine production, wash-out via circulation, and decay, respectively.
For all the diffusion equations, as well as the pressure and angiogenic factors, the
conditions at the boundaries are (zero Neumann condition), where N is the element at the
boundary (oxygen, pressure, or chemokine).
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4. Movement
Monocytes as well as M1 and M2 macrophages migrate through the interstitium
guided by gradients of oxygen, pressure, and chemoattractants. Movement in one of four
directions is determined semi-stochastically, similar to the differentiation algorithm
above. The probability of movement in the x+1 direction is as follows:

𝑃𝑥+1 = (𝑀𝑂 ∙ ∆𝑂𝑥+1 + 𝑀𝑃 ∙ ∆𝑃𝑥+1 + 𝑀𝐶 ∙ ∆𝐶ℎ𝑒𝑚𝑜𝑥+1 )

(12)

where 𝑀𝑂 , 𝑀𝑃 and 𝑀𝐶 are intensity coefficients for the influence of oxygen
concentration, pressure, and chemoattractant on macrophage movement (see Table),
and ∆𝑂𝑥+1 , ∆𝑃𝑥+1 and ∆𝐶ℎ𝑒𝑚𝑜𝑥+1 are the difference in concentration of the factor of
interest from the current point to the direction in question. The same calculations are
made for the remaining three directions in the 2D Cartesian grid. A random number is
then generated which may fall into the interval calculated for one of these four directions.
Otherwise, the macrophage remains in place.
The method of movement for the TEM is also semi-stochastic, but relies upon a
different chemoattractant – Ang2 gradients secreted by the neovasculature. The
probability of movement in the x+1 direction is modeled as follows:

𝑃𝑥+1 = 𝑀𝐴𝑛𝑔2 ∙ ∆𝐴𝑛𝑔2𝑥+1

(13)
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where 𝑀𝐴𝑛𝑔2 is the intensity coefficient tuned to scale the response of TEMs to the Ang2
concentration gradient in each direction.
TABLE VIII
MACROPHAGE MOVEMENT SCALING COEFFICIENTS
𝑀𝑂
𝑀𝑃
𝑀𝐶
𝑀𝐴𝑛𝑔2

Effect of oxygen on macrophage movement
Effect of oxygen on macrophage movement
Chemotactic macrophage movement
Effect of Ang2 on TEM movement

1000
500
350
1000

(Leonard, Curtis et al. 2016)
(Leonard, Curtis et al. 2016)
(Leonard, Curtis et al. 2016)
Calibrated to match (De Palma
and Naldini 2011)

Note: (*) Value is rescaled by the square of the simulation system characteristic length (1
cm) and divided by the system characteristic time (1 sec) multiplied by the oxygen
diffusivity (Nugent and Jain) (1 x 10-5 cm2 s-1).

D. Numerical Methods
A detailed description of the numerical methods employed in the model is given
in (Wu, Frieboes et al.) and Macklin (Macklin, McDougall et al.) and their incorporated
references. The continuous equations governing gradients of oncotic pressure by which
the tumor advances, as well as diffusion of oxygen, TAF, chemokines, and other factors
are applied to a discrete 2D Cartesian grid via backward Euler’s method with centered
finite difference calculations. Discretization of the change in pressure at the boundary
between oncotic and normal tissue, an immersed moving boundary with jump boundary
conditions, is applied by a ghost cell method described in (Macklin and Lowengrub) .
The resulting discretized equations are then solved to steady state at time steps of
0.075 days (Wu, Frieboes et al.) according to a nonlinear adaptive Gauss-Seidel iteration
method (Macklin and Lowengrub , Macklin and Lowengrub) to produce, at each grid
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location, values for concentrations of diffusible factors, oncotic pressure, and interstitial
fluid pressure outside the tumor.
To map the changing curved topology of the boundaries between tumor
hypoxic/normoxic regions and tumor and normal tissue, the level set method is used.
The vessel radii calculated at each iteration influence the blood flow, which in turn
modulates the hematocrit in the angiogenesis component, which affects the extravasation
of monocytes and oxygen from the vasculature. The monocytes and macrophages in
(Leonard, Curtis et al.) were originally modeled as point sources of drug. In this instance,
macrophages do not release active drug into the system, but rather IL-10, M2GF, and
NO. The monocytes are not biologically active in this model.
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RESULTS
The tumor, vascular, and macrophage parameters were calibrated as described
above. The single and combined effects of the three macrophage types on tumor growth
were then evaluated, as described in the following table:

TABLE IX
SUMMARY OF MACROPHAGE CASES EVALUATED
Variation 1
M1

Variation 2

Variation 3
M1

M2
TEM

M2
TEM

M2

Variation 4
M1

Variation 5

Variation 6

Variation 7
M1

Variation 8
none

M2
TEM

TEM

A case to match in vivo macrophage ratios was first run, with all three
macrophage subtypes present (Variation 1). The other cases then examined the tumoral
response to other population variants. Variation 2 and 5 represent worst-case subtype
populations – the tumorigenic subtype M2 or M2 and TEM only, driving unrestrained
tumor growth. Variation 3 is the TEM-ablated model, utilizing M1 and M2 only.
Variation 4 is the best-case population, with the tumoricidal subtype M1 only.
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Variation 6 examined the vascular protective effects of TEM alone without its
effects on M1 and M2 populations. Variation 4 utilizes the tumoricidal subtype M1 and
immunomodulatory TEM only. Finally, macrophage activity is entirely absent in
Variation 8, providing a baseline tumor growth profile.
Each was observed over a simulated 13.5-day timespan of tumor growth.

A. Interaction with blood vessels
Following the Ang2 gradient secreted by the neovasculature (Fig. 1, bottom right
panel), the TEMs in variations 1, 2, 4, and 7 preferentially clustered around angiogenic
vessels (Fig. 1, middle right panel). Here, they prevented vessel collapse due to the
increased pressure of the tumor environment (Fig. 1, top middle panel) as expressed in
Equation 6.
The extravasation of monocytes and subsequent macrophage differentiation is
triggered by the release of TAF from the hypoxic interior of the tumor (Fig. 1, bottom left
panel). This first occurred when the lesion reached 200 µm in diameter (Day 7.35 of
growth). All four models had the same tumoral and vascular growth pattern until this
time, whereupon they began to diverge.
Fig. 1 provides a representative assessment of tumor growth, vascular
development, macrophage infiltration, and key secreted factors at 13 days post-inception
in Variation 1.
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FIGURE 1 – REPRESENTATIVE ASSESSMENT OF TUMOR GROWTH
B. Macrophage ratios
The effect of the TEM subtype on macrophage differentiation can be observed in
where the M1 and M2 subtypes are clustered. The M1 subtypes are mostly concentrated
within the tumor lesion, while the M2 subtypes are in the immediate periphery as a
consequence of the monocyte contact with IL-10 eluted from TEMs (see Fig.1, top right
panel, and Fig 2.). The TEM subtypes cluster around angiogenic vessel sprouts as a
result of the Angiopoietin2 secreted by the neovasculature.
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FIGURE 2 – MACROPHAGE DISTRIBUTIONS RELATIVE TO TUMOR
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In variation 1, TIE2 expressing macrophages differentiating from the monocyte
precursors became the majority subset in the tumor environment at 60.1%, matching in
vivo data . In Variation 3 - M1 and M2 only - the M2/M1 ratio stabilized at 0.85. This
ratio is half the median ratio for highly metastatic tumors, and within the normal range
for more benign tumor populations (Cui 2013). A comparison of the two models shows
that by modeling an increase in IL-10 in response to the IL-10 secreted by the TEMs, the
M2/M1 ratio was shifted to 1.71 - a ratio consistent with more metastatic tumors (Cui
2013). The proportion of different macrophage types in time is shown in Fig. 3 and 4.

70%

% of Sutypes Present

60%
50%
TEM

40%

M2

30%

M1

20%
10%
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Day of Growth

FIGURE 3 – MACROPHAGE RATIOS IN VARIATION 1
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FIGURE 4 – MACROPHAGE RATIOS IN VARIATIONS 1 AND 3

C. Angiogenesis
Due to the protective clustering around angiogenic vasculature (see Fig. 1 middle
right panel), variations with the TEM subtype displayed notably greater vascular
development compared to the corresponding TEM-absent variations. Comparing
variations 1 and 3, in which TEM is respectively present and ablated (Fig 5) a 3.81-fold
increase in tumoral vasculature is observed, consistent with the nearly four-fold increase
found by De Palma et al. in an analogous study in vivo (De Palma, Venneri et al.).
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FIGURE 5 – INTRATUMORAL VASCULATURE BY VARIATION

As expected, variations with the TEM subtype present displayed greater vascular
growth at the endpoint of the simulation, compared with those which did not. The
presence of the M2 macrophage also encouraged vascular development, due to the
increased size of the tumor achieved.

D. Tumor Radius
The effects of the TIE2 subtype on M1/M2 ratio and angiogenic protection in
concert had a noticeable effect on the tumor progression (Fig. 6).

30

0.25
M2

0.225

Tumor Radius (mm)

M2 TEM
0.2

M1 M2 TEM
M1 M2

0.175

NONE
0.15

TEM
M1 TEM

0.125

M1
0.1
7.20

8.20

9.20

10.20

11.20

12.20

13.20

Day of Growth

FIGURE 6 – TUMOR RADII BY VARIATION

Variation 1 with all three subtypes yielded an 11.9% increase in tumor radius over
Variation 3, the TEM-ablated model, by the end of the simulation. The TEM-ablated
variations showed a plateau in growth around Day 10. Variations 2 and 5, with TEM and
M2, and M2 respectively, exhibited the strongest growth. This growth held steady to the
end of the simulation, despite the development of hypoxic and necrotic regions within the
tumor lesion (see Appendix IV). Variation 4, with M1 only, showed the least tumor
growth, exhibiting a plateau consistent with findings of M1-only in vivo (Yuan, Hsiao et
al.).
While all variations achieved a size that at least transiently rendered the interior
portions hypoxic, only those with the TEM subtype and/or the M2 subtype were able to
achieve continued growth through the end of the simulation (see Fig 6 and Fig 7). This
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would indicate that the role of TEM in tumor vascularization mitigates an important
immune-mediated check to unbounded tumoral growth.
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FIGURE 7 – PROLIFERATING AND HYPOXIC REGIONS
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DISCUSSION

In this study, mathematical modeling was employed to explore the tumorpromoting and tumor-inhibiting roles of three major tumor-associated macrophage
subtypes. A small metastatic lesion in the liver was simulated, growing in a highlyvascularized microenvironment, coupling the feedback between the tumor tissue,
vasculature remodeling, and the macrophage activity. This work could provide a
modeling platform for system analysis of the potent and varied effects of the macrophage
activation spectrum on the tumor microenvironment, and presents the possibility of a
valuable complement to current cancer therapy design. Given the ability of tumors to
educate infiltrating macrophages to a tumorigenic subtype, methods of countering this
may prevent the tumor from harnessing the body’s most potent effectors of tissue
remodeling as has been previously suggested (Quatromoni and Eruslanov 2012).
According to this paradigm, therapies which inhibit all monocytes and
macrophages that infiltrate the tumor environment would be unideal, as they would fail to
utilize the inherent tumoricidal activity of M1 macrophages. However, a more finessed
approach by removal of the phenotypically and developmentally distinct TIE-2
expressing monocyte may be a more desirable and plausible target. Since this subset is
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also implicated in the facilitation of cancer metastasis by degrading the ECM and guiding
metastatic cells to the vasculature (e.g., as observed with breast cancer (Williams, Yeh et
al. 2016)), blockade of this subtype from the tumor microenvironment may be a valuable
target for both halting and reversing the metastatic progression of cancer in a patient
(Venneri, Palma et al. 2007).
Additionally, the action of the TEM subtype may in part explain the pitfalls that
have been observed in the use of VEGF inhibitors for tumor therapy (Vasudev and
Reynolds 2014). In some instances, due to the tendency of inhibited tumoral blood supply
to lead to increased tumor spread through fragmentation and migration of tumor cells,
preventing the vasculature from growing towards the tumor could force a more malignant
and metastatic phenotype, as has been observed experimentally (Rubenstein, Kim et al.
2000, Kunkel, Ulbricht et al. 2001, Lamszus, Kunkel et al. 2003, Pennacchietti, Michieli
et al. 2003, Stockmann, Doedens et al. 2008, Ebos, Lee et al. 2009, Paez-Ribes, Allen et
al. 2009, de Groot, Fuller et al. 2010), clinically (de Groot, Fuller et al. 2010, Sharpe,
Stewart et al. 2013), and predicted by mathematical modeling (Cristini, Lowengrub et al.
2003, Cristini, Frieboes et al. 2005, Frieboes, Zheng et al. 2006, Wise, Lowengrub et al.
2008, Frieboes, Jin et al. 2010, Lowengrub, Frieboes et al. 2010).
Given that TEMs differentiate from a monocyte precursor distinct from the M1
and M2 subtypes, the possibility of TEM-specific therapies presents a promising method
of fine-tuning the immune system’s innate defense mechanisms without preventing the
action of tumoricidal subtypes (Mantovani and Allavena 2015). This would educate the
tumor to a more benign phenotype, rather than allowing it to alter the immune response to
aid its malignancy.
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RECOMMENDATIONS
Future work will explore the interaction of tumor and macrophage effects during
treatment. Therapy could be delivered systemically as free drug or encapsulated in
nanovectors, as previously simulated (Wu, Frieboes et al. 2014, Curtis, Wu et al. 2015,
Curtis, England et al. 2016, Curtis, van Berkel et al. 2017), or its delivery to the tumor
site could be targeted by tumor-associated macrophage uptake and release (Leonard,
Curtis et al. 2016). Pharmaceutical ablation of tumor-promoting subtypes while
supporting tumor-inhibiting phenotypes could provide further therapeutic options.
The combination of various modalities could be explored via the modeling
framework presented herein, as such options would be difficult to evaluate solely through
experimental observation. With input of patient tumor-specific information, such as size,
vascularization, and macrophage density, this framework may in the longer term be of
use to determine optimal therapy regimens leveraging the body’s immune response to
metastatic lesions.
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